A Study of PN20 in Healthy Adult Volunteers

A Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of PN20 in Healthy Adult Volunteers

The main aim of this clinical trial is to assess the safety of PN20 in healthy volunteers aged 18 to 50 years. The main questions it aims to answer are:

• Is PN20 safe in adult? Researchers will compare PN20 to a placebo (a look-alike substance that contains no drug) to see if PN20 is safe.

Participants will

• Receive a single dose injection of PN20 or placebo according to weight,
• Stay in hospital for assessment.

Study Overview

• Status: Completed
• Conditions: Immune Thrombocytopenic Purpura; Chemotherapy-induced Thrombocytopenia
• Intervention / Treatment: Drug: PN20; Drug: Placebo

Detailed Description

This is a single center, randomized, double-blind, placebo-controlled, dose escalation phase 1 clinical study, aiming to evaluate the efficacy, safety, immunogenicity and pharmacokinetic of PN20 in healthy volunteers.

• Study Type: Interventional
• Enrollment (Actual): 27
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Jiangshu
    • Suzhou, Jiangshu, China, 215006
      • The First Affiliated Hospital of Soochow University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Healthy male or female subjects aged 18 to 50 years;
2. Body mass index between 19.0-28.0 (inclusive), body mass index (BMI) = weight (kg)/height^2 (m^2);
3. Female subjects of childbearing age with negative serum pregnancy test results;
4. Platelet counts during the screening period and one day before enrollment are within the range of 100-300×10^9/L;
5. Eligible subjects of fertility must agree to use effective contraceptive measures or abstain from sex within 6 months after receiving the investigational drug;
6. Be able to understand and comply with the requirements of the protocol and expected to complete the entire trial process;
7. Voluntarily participate and sign the informed consent form.

Exclusion Criteria:

1. Abnormal results of vital signs examination with clinical significance determined by the investigator;
2. Positive test results for HIV-Ab, HCV-Ab, HBsAg, HBeAg, or treponema pallidum antibodies;
3. Abnormal results of laboratory test (blood routine, urine routine, blood biochemistry, coagulation) with clinical significance determined by the investigator;
4. Abnormal electrocardiogram with clinical significance or prolonged QT/QTc interval is, such as QTcB ≥ 430ms (male), or QTcB ≥ 450ms (female) (machine reading results); family history of QT prolongation;
5. Positive drug abuse test or alcohol test ≥20mg/dL;
6. Abnormal results of chest CT or COVID-19 screening (nucleic acid and C-reactive protein) with clinical significance determined by the investigator;
7. Have taken any drugs (including prescription drugs, over-the-counter drugs and Chinese herbal medicines) within 4 weeks before enrollment, except for external drugs that are not absorbed by the body;
8. Have used drugs known to cause significant damage to certain organs within 12 weeks before enrollment;
9. Participated, enrolled and been administered in other clinical trials within 3 months before enrollment, or used this investigational drug or similar drugs;
10. Received live attenuated vaccines within 28 days before administration of the trial drug and/or received inactivated vaccines within 7 days before administration, and/or plan to receive vaccines during the trial;
11. Allergic constitution, or history of drug allergy, or history of allergy to the ingredients of this investigational drug;
12. Have a history of major surgery or a history of blood donation ≥200 mL within 12 weeks before enrollment or who plan to donate blood during the study;
13. Have a history of any serious clinical disease, including but not limited to diseases of the digestive system, cardiovascular system, respiratory system, urinary system, musculoskeletal system, endocrine system, neuropsychiatric system (such as epilepsy, dementia, etc.), blood system, and immune system And those with a history of metabolic abnormalities, deep vein thrombosis, thrombocytopenia, thrombocythemia, platelet dysfunction, etc.;
14. Smoke more than 5 cigarettes a day or have a history of alcohol abuse in the 6 months before enrollment, that is, drink more than 14 units of alcohol per week (1 unit = 12 ounces or 360mL of beer, 1.5 ounces or 45mL of hard liquor with 40% alcohol content, 5 ounces or 150mL of wine);
15. Drink more than 1L of strong tea, coffee and/or caffeinated beverages every day;
16. Cannot tolerate venipuncture blood collection or have a history of needle or blood fainting;
17. Lactating, pregnant or planning to become pregnant or conceive in the near future;
18. The investigator believes the subject would be unsuitable for participation in this clinical study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PN20 group; subcutaneous injections, a single dose	Drug: PN20; Six dose levels of PN20 will be evaluated; Other Names: thrombopoietin receptor agonist
Placebo Comparator: Placebo group; subcutaneous injections, a single dose	Drug: Placebo; Placebo of PN20

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Treatment-related Adverse Events	Number of participants with treatment-related adverse events during the study will be collected and the percentage of AE of different grades as assessed by CTCAE v5.0 will be assessed.	up to 15 days

Collaborators and Investigators

• Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd.
• Investigators: Principal Investigator: LiYan Miao, The First Affiliated Hospital of Soochow University

Study record dates

Study Major Dates

• Study Start (Actual): June 16, 2022
• Primary Completion (Actual): January 5, 2023
• Study Completion (Actual): January 5, 2023

Study Registration Dates

• First Submitted: July 22, 2024
• First Submitted That Met QC Criteria: July 22, 2024
• First Posted (Actual): July 26, 2024

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 11, 2025
• Last Verified: July 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cytopenia; Pathologic Processes; Autoimmune Diseases; Immune System Diseases; Hemorrhage; Skin Manifestations; Hematologic Diseases; Blood Coagulation Disorders; Hemorrhagic Disorders; Blood Platelet Disorders; Thrombotic Microangiopathies; Thrombocytopenia; Purpura; Purpura, Thrombocytopenic, Idiopathic; Purpura, Thrombocytopenic
• Other Study ID Numbers: 2021-PK-PN20-32

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No